Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 3,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 7 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Individual Disclosed balance after: 3,343 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F8 · ownership.nature: Shares held directly by Daniel Tafur ("Mr. Tafur"). Mr. Tafur is chief investment officer, founder and board member of Equilibria and may be deemed to beneficially own shares beneficially owned by Equilibria. Mr. Tafur disclaims beneficial ownership of securities beneficially owned by Equilibria, except to the extent of any pecuniary interests therein. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 3,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 6 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By limited liability company Disclosed balance after: 3,343 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F7 · ownership.nature: Shares held by Varibobi Financial Holdings Limited, a Cyprus limited liability company ("Varibobi"). Varibobi is an owner of Equilibria and may be deemed to beneficially hold shares beneficially owned by Equilibria. Fabio Lopez is the sole owner of Varibobi and the chief executive officer and a board member of Equilibria and may be deemed to be the indirect beneficial owner of the shares owned by Varibobi and Equilibria. Mr. Lopez disclaims beneficial ownership of securities beneficially owned by Equilibria, except to the extent of any pecuniary interests therein. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 58,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 5 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 58,208 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F6 · ownership.nature: Shares held directly by EQC Private Markets II SAC Fund Ltd EQC Biotech Sely III Fund ("Sely III"), a Bermuda mutual fund company. Equilibria manages Sely III and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 325,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 4 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 325,799 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F5 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund Ltd EQC Biotech Sely II Fund, ("Sely II"), a Bermuda mutual fund company. Equilibria manages Sely II and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 676,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 3 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 676,324 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F4 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund Ltd EQC Biotech Sely I Fund, ("Sely I"), a Bermuda mutual fund company. Equilibria manages Sely I and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 1,521,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 2 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 1,521,863 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F3 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund II Ltd EQC Biotech Sely S Fund ("Sely S"), a Bermuda mutual fund company. Equilibria manages Sely S and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC |
Lopez FabioDirector · 10% owner
Equilibria Capital Management Ltd10% owner
Castilian Ltd.10% owner
Varibobi Financial Holdings Ltd10% owner
Tafur Daniel10% owner
|
GrantCommon Stock | 149,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 1 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By limited liability company Disclosed balance after: 149,766 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F2 · ownership.nature: Shares held directly by Equilibria Capital Management Limited ("Equilibria"), a Bermuda limited liability company. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:11 UTC |
SCHEINBERG DAVID ADirector
|
GrantCommon Stock | 9,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067659 · doc4.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,107 F1 · price: In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS. F2 · balance_after: Represents shares issuable upon vesting of RSUs. 100% of the shares subject to the RSUs will vest on February 27, 2018. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 22:12 UTC |
Stergiou Angelos M.Director · President and CEO
|
GrantCommon Stock | 450,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067660 · doc4.xml · nonDerivative · entry 1 Stergiou Andelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,135 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. Read SEC document |
| December 29, 2017 Filed Mar 16, 2018 16:31 UTC Amendment |
SCHEINBERG DAVID ADirector
|
GrantCommon Stock | 9,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020187 · doc4a.xml · nonDerivative · entry 1 SCHEINBERG DAVID A · CIK 0001250316 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,107 F1 · price: In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS. F2 · balance_after: Represents shares issuable upon vesting of RSUs. The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon a liquidity event as defined in the award agreement) and (b) time-based vesting restrictions (100% of the RSUs satisfied the time-based vesting restrictions on February 27, 2018). The Merger did not constitute a liquidity event for the performance-based vesting restrictions. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 21:48 UTC |
Ashton WilliamDirector
|
GrantCommon Stock | 15,472 | $0.38 | $5,879.36 |
DisclosureSEC source: 0001394548-17-000028 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,154 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 18:01 UTC |
Nisi RudolphDirector
|
GrantCommon Stock | 17,130 | $0.38 | $6,509.40 |
DisclosureSEC source: 0001394548-17-000033 · primary_doc.xml · nonDerivative · entry 1 Nisi Rudolph · CIK 0001297775 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,918 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 17:56 UTC |
Hillsberg SanfordDirector
|
GrantCommon Stock | 20,997 | $0.38 | $7,978.86 |
DisclosureSEC source: 0001394548-17-000031 · primary_doc.xml · nonDerivative · entry 1 Hillsberg Sanford · CIK 0001297696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,950 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 21:59 UTC |
GRAY MARY ANNDirector
|
GrantCommon Stock | 15,472 | $0.38 | $5,879.36 |
DisclosureSEC source: 0001394548-17-000032 · primary_doc.xml · nonDerivative · entry 1 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,167 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 17:54 UTC |
GALLIKER STEPHEN SDirector
|
GrantCommon Stock | 13,814 | $0.38 | $5,249.32 |
DisclosureSEC source: 0001394548-17-000030 · primary_doc.xml · nonDerivative · entry 1 GALLIKER STEPHEN S · CIK 0001249422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,039 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 21:45 UTC |
Chin RichardDirector
|
GrantCommon Stock | 12,708 | $0.38 | $4,829.04 |
DisclosureSEC source: 0001394548-17-000027 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,339 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 21:51 UTC |
Einhorn Irving M.Director
|
GrantCommon Stock | 14,366 | $0.38 | $5,459.08 |
DisclosureSEC source: 0001394548-17-000029 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,690 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:44 UTC |
Ashton WilliamDirector
|
GrantCommon Stock | 9,866 | $0.59 | $5,820.94 |
DisclosureSEC source: 0001394548-17-000025 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,682 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 17:19 UTC |
Nisi RudolphDirector
|
GrantCommon Stock | 10,924 | $0.59 | $6,445.16 |
DisclosureSEC source: 0001394548-17-000020 · primary_doc.xml · nonDerivative · entry 1 Nisi Rudolph · CIK 0001297775 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,788 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 17:36 UTC |
Hillsberg SanfordDirector
|
GrantCommon Stock | 13,390 | $0.59 | $7,900.10 |
DisclosureSEC source: 0001394548-17-000023 · primary_doc.xml · nonDerivative · entry 1 Hillsberg Sanford · CIK 0001297696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,953 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:23 UTC |
GRAY MARY ANNDirector
|
GrantCommon Stock | 9,866 | $0.59 | $5,820.94 |
DisclosureSEC source: 0001394548-17-000021 · primary_doc.xml · nonDerivative · entry 1 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,695 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 17:41 UTC |
GALLIKER STEPHEN SDirector
|
GrantCommon Stock | 8,809 | $0.59 | $5,197.31 |
DisclosureSEC source: 0001394548-17-000024 · primary_doc.xml · nonDerivative · entry 1 GALLIKER STEPHEN S · CIK 0001249422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,225 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:30 UTC |
Chin RichardDirector
|
GrantCommon Stock | 8,104 | $0.59 | $4,781.36 |
DisclosureSEC source: 0001394548-17-000022 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,631 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:47 UTC |
Einhorn Irving M.Director
|
GrantCommon Stock | 9,161 | $0.59 | $5,404.99 |
DisclosureSEC source: 0001394548-17-000026 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,114 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 17:37 UTC |
Nisi RudolphDirector
|
SaleCommon Stock | 500 | $0.55 | $273.05 |
DisclosureSEC source: 0001394548-17-000019 · primary_doc.xml · nonDerivative · entry 1 Nisi Rudolph · CIK 0001297775 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,864 Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:44 UTC |
Ashton WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000025 · primary_doc.xml · derivative · entry 2 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 17:19 UTC |
Nisi RudolphDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000020 · primary_doc.xml · derivative · entry 2 Nisi Rudolph · CIK 0001297775 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 17:36 UTC |
Hillsberg SanfordDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000023 · primary_doc.xml · derivative · entry 2 Hillsberg Sanford · CIK 0001297696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:23 UTC |
GRAY MARY ANNDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000021 · primary_doc.xml · derivative · entry 2 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 17:41 UTC |
GALLIKER STEPHEN SDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000024 · primary_doc.xml · derivative · entry 2 GALLIKER STEPHEN S · CIK 0001249422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:30 UTC |
Chin RichardDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000022 · primary_doc.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:47 UTC |
Einhorn Irving M.Director
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000026 · primary_doc.xml · derivative · entry 2 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:53 UTC |
Ashton WilliamDirector
|
GrantCommon Stock | 9,870 | $0.59 | $5,823.30 |
DisclosureSEC source: 0001394548-17-000012 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,816 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan, priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 17:11 UTC |
Nisi RudolphDirector
|
GrantCommon Stock | 10,927 | $0.59 | $6,446.93 |
DisclosureSEC source: 0001394548-17-000018 · primary_doc.xml · nonDerivative · entry 1 Nisi Rudolph · CIK 0001297775 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,364 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 17:06 UTC |
Hillsberg SanfordDirector
|
GrantCommon Stock | 13,394 | $0.59 | $7,902.46 |
DisclosureSEC source: 0001394548-17-000016 · primary_doc.xml · nonDerivative · entry 1 Hillsberg Sanford · CIK 0001297696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,563 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 21:08 UTC |
GRAY MARY ANNDirector
|
GrantCommon Stock | 8,815 | $0.59 | $5,200.85 |
DisclosureSEC source: 0001394548-17-000017 · primary_doc.xml · nonDerivative · entry 1 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,829 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 17:02 UTC |
GALLIKER STEPHEN SDirector
|
GrantCommon Stock | 9,865 | $0.59 | $5,820.35 |
DisclosureSEC source: 0001394548-17-000015 · primary_doc.xml · nonDerivative · entry 1 GALLIKER STEPHEN S · CIK 0001249422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,416 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:56 UTC |
Chin RichardDirector
|
GrantCommon Stock | 8,107 | $0.59 | $4,783.13 |
DisclosureSEC source: 0001394548-17-000013 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,527 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:59 UTC |
Einhorn Irving M.Director
|
GrantCommon Stock | 8,638 | $0.59 | $5,096.42 |
DisclosureSEC source: 0001394548-17-000014 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,953 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:16 UTC |
Hudson Bay Capital Management LP10% owner
Gerber Sander10% owner
|
PurchaseCall Options (obligation to sell) · Derivative | 1,100 | $33,000.00 Strike: $1.00 | $36,300,000.00 |
DisclosureSEC source: 0000902664-17-001037 · p17-0701form4.xml · derivative · entry 2 Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner Gerber Sander · CIK 0001416593 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: Not disclosed Underlying: Common Stock · 110,000 shares Expires 2019-01-18 F3 · derivative.exercise_date: Exercisable at any time. F2 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 18:16 UTC |
Hudson Bay Capital Management LP10% owner
Gerber Sander10% owner
|
SaleCommon Stock, par value $0.001 per share ("Common Stock") | 2,363,441 | $0.84 | $1,985,290.44 |
DisclosureSEC source: 0000902664-17-001037 · p17-0701form4.xml · nonDerivative · entry 1 Hudson Bay Capital Management LP · CIK 0001393825 · 10% owner Gerber Sander · CIK 0001416593 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,036,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.10 to $0.83, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The securities are held by Hudson Bay Master Fund, Ltd. (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 16:58 UTC |
Knapp Thomas JGeneral Counsel
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001394548-17-000011 · primary_doc.xml · derivative · entry 1 Knapp Thomas J · CIK 0001311726 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-06 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · derivative.exercise_date: This stock option will vest in equal, monthly installments over 8 months beginning May 1, 2017 through December 31, 2017, so long as the Reporting Person remains in the company's continuous employ through the vesting period. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 23:07 UTC |
Ashton WilliamDirector
|
GrantCommon Stock | 2,946 | $1.98 | $5,833.08 |
DisclosureSEC source: 0001394548-17-000008 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,946 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 18:02 UTC |
Nisi RudolphDirector
|
GrantCommon Stock | 3,262 | $1.98 | $6,458.76 |
DisclosureSEC source: 0001394548-17-000006 · primary_doc.xml · nonDerivative · entry 1 Nisi Rudolph · CIK 0001297775 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,437 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 18:05 UTC |
Hillsberg SanfordDirector
|
GrantCommon Stock | 3,998 | $1.98 | $7,916.04 |
DisclosureSEC source: 0001394548-17-000007 · primary_doc.xml · nonDerivative · entry 1 Hillsberg Sanford · CIK 0001297696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,169 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 23:12 UTC |
GRAY MARY ANNDirector
|
GrantCommon Stock | 2,525 | $1.98 | $4,999.50 |
DisclosureSEC source: 0001394548-17-000009 · primary_doc.xml · nonDerivative · entry 1 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,004 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 17:56 UTC |
GALLIKER STEPHEN SDirector
|
GrantCommon Stock | 3,051 | $1.98 | $6,040.98 |
DisclosureSEC source: 0001394548-17-000004 · primary_doc.xml · nonDerivative · entry 1 GALLIKER STEPHEN S · CIK 0001249422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,551 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 23:00 UTC |
Chin RichardDirector
|
GrantCommon Stock | 2,420 | $1.98 | $4,791.60 |
DisclosureSEC source: 0001394548-17-000005 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,420 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 25, 2017 00:27 UTC |
Einhorn Irving M.Director
|
GrantCommon Stock | 2,525 | $1.98 | $4,999.50 |
DisclosureSEC source: 0001394548-17-000010 · primary_doc.xml · nonDerivative · entry 1 Einhorn Irving M. · CIK 0001603271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,525 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 19:44 UTC |
Nejadnik BijanChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001394548-17-000003 · primary_doc.xml · derivative · entry 1 Nejadnik Bijan · CIK 0001657705 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-17 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · derivative.exercise_date: This stock option will vest in 16 equal, quarterly installments over four years, beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.